Genmab — Juni 2023

[E_L]

Both Talquetamab and Epcoritamab on the COMP agenda for next week under '4. Review of orphan designation for orphan medicinal products
at time of initial marketing authorisation' https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-june-2023_en.pdf

[E_L]

results from 2 cohorts in EPCORE NH2 investigating epcoritamab+rituximab & lenalidomide in patients with R/R FL. This combination showed potent anti-tumor activity and a manageable safety profile in patients with high-risk disease #lymsm https://twitter.com/lymphomahub/status/1667162491560837120

[E_L]

@NBahlis
presents results of the TRIMM-2 trial (talquetamab + daratumumab), targeting GPRC5D & CD38, ORR of 84% w/ response rate within 1st round of therapy.
**Impressively, 78.6% pts were refractory & heavily pre-exposed to a CD38 https://twitter.com/MyelomaCanada/status/1667475172201201664 https://twitter.com/MM_Hub/status/1667475083022024707

[E_L]

Follicular #lymphoma (#FL) accounts for ~20% of all non-Hodgkin’s lymphoma (NHL) cases globally and is the most common subtype of indolent, or slow growing, NHL. https://twitter.com/Genmab/status/1667275399364001793

[Bulder]

Carvykti: https://haematologisktidsskrift.dk/sygdomme/myeloma/1190-finale-cartitude-1-data-storste-pfs-gevinst-for-tungt-forbehandlede-rrmm-patienter-til-dato.html. https://haematologisktidsskrift.dk/sygdomme/myeloma/1194-forste-data-fra-cartitude-4-meget-flotte-responser-hos-lenalidomid-refraktaere-myelomatose-patienter.html

[Klarussen]

Dejligt at se

[E_L]

EPCORE FL-1 closes further enrollment to one of the groups ; i assume this means the correct dose is found and they no longer need to continue that cohort. Saves recruitement of 122 patients as Enrollment goes from 642 to 520 https://www.clinicaltrials.gov/ct2/history/NCT05409066?A=47&B=48&C=merged#StudyPageTop

[E_L]

New trial - Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial https://www.clinicaltrials.gov/ct2/show/NCT05898646

[Bulder]

Looks like they already now know that dose A is better than dose B. They just need to find out HOW much better. Or could it be the other way round?

[E_L]

that is also what i thought
Bulder

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[Pensionisten]

Så er det vel i aften, der er Fireside hos GS https://event.webcasts.com/starthere.jsp?ei=1618997&tp_key=ab369db32b&tp_special=8

[Bulder]

Opdaterede EPCORE NHL-2-data støtter op om epcoritamab + R-CHOP i 1L til højrisiko DLBCL https://haematologisktidsskrift.dk/sygdomme/lymfoma/1201-opdaterede-epcore-nhl-2-data-stotter-op-om-epcoritamab-r-chop-i-1l-til-hojrisiko-dlbcl.html

[JKY_VH]

tak Bulder

[Bulder]

Men der er lang tid til vi ser data fra fase 3-studiet. Først startet i år.

[E_L]

Genmab, l'autre success-story danoise de la santé https://www.zonebourse.com/cours/action/GENMAB-A-S-63733191/actualite/Genmab-l-autre-success-story-danoise-de-la-sante-44098213/?utm_medium=RSS&utm_source=googlenews&utm_content=20230613

[Mogan]

Hvor mon vi har bunden denne gang? Så der kan købes ind

[JKY_VH]

Det plejer SB at have et kvalificeret bud på.

[Riis7]

Flot sidste plads i c25 i år
efter snart 6 mån, men var os vinder sidste år sammen med Novo:-) Novo har så klaret sig noget bedre i år:-)